DBV Technologies Shares Drop 2% to €3.41 but Maintain a +75% Yearly Gain
DBV Technologies' stock falls by 2.01% to €3.41 in early afternoon trading, within a nearly stable SBF 120 (-0.13%). The French biotech ranks 118th in the broad index, among the top 5 biggest declines of the session. The stock has dipped below its short-term moving averages after several weeks of consolidation around €3.50.
A Decline That Brings the Stock Back to Its €3.34 Support
DBV Technologies loses 2.01% to €3.41, at the lower end of its Bollinger Bands (31% of the band, lower boundary at €3.25). The price is now below the MM20 (€3.51) and MM50 (€3.57), with a respective gap of 2.85% and 4.48%. The RSI at 51 remains neutral, signaling neither overselling nor bullish momentum.
The support at €3.34 is approaching, less than 2% below the current price. Over three months, the performance has declined by 7.59%, but the gain over one year remains at 75.59%, driven by the underlying momentum that marked the end of 2025 and the beginning of 2026. The MM200, at €2.84, remains 20% below the price, indicating that the medium-term trend is not compromised by today's movement.
Busy Regulatory Calendar and Secured Treasury Until 2027
The French biotech is progressing with a busy 2026 schedule for its Viaskin Peanut patch. Two submissions for biological license applications are expected at the FDA this year, one for children aged 4 to 7 and another for toddlers aged 1 to 3, according to the schedule announced in early May. A phase 2 study in infants aged 6 to 12 months is also planned.
In terms of financing, the company has $229 million in cash as of March 31, 2026, following the full exercise of warrants from the private placement in March 2025. This position covers needs until the second quarter of 2027. Regarding analysts, Kempen maintained a buy recommendation in early May while lowering its price target from €11 to €9. Next events: the mixed general meeting on June 3, 2026, followed by the semi-annual results on July 29.
